BCD-147

BCD-147 is a bispecific anti-HER2 monoclonal antibody developed by Biocad. It functions as an antagonist of the HER2 (also known as ERBB2 or receptor tyrosine-protein kinase erbB-2) receptor, which is implicated in various cancers due to its role in cell growth and differentiation. The drug's primary mechanism of action is inhibition of HER2 signaling through antagonism at the receptor level. As of June 2025, BCD-147 has completed phase 1 clinical trials evaluating its safety, pharmacokinetics, and immunogenicity in healthy volunteers. No approved indications or marketed status are reported for this agent[1][3][6].